Abstract:Aims/hypothesis The aim of this work was to define a unique remission status using glycaemia risk index (GRI) and other continuous glucose monitoring (CGM) metrics in individuals with type 1 diabetes for improved phenotyping.Methods A group of 140 individuals with type 1 diabetes were recruited for a cross-sectional study. The participants were categorised into four groups based on their remission status, which was defined as insulin-dose-adjusted A1c (IDAA1c) <9 or C-peptide >= 300 pmol/l: new-onset (n=24); mid-remission (n=44); post-remission (n=44); and non-remission (individuals who did not experience remission, n=28). Participants in the remission phase were referred to as 'remitters', while those who were not in the remission phase were referred to as 'non-remitters', the latter group including new-onset, post-remission and non-remission participants. Clinical variables such as HbA(1c), C-peptide and insulin daily dose, as well as IDAA1C and CGM data, were collected. The patterns of CGM metrics were analysed for each group using generalised estimating equations to investigate the glycaemic variability patterns associated with remission status. Then, unsupervised hierarchical clustering was used to place the participants into subgroups based on GRI and other CGM core metrics.Results: The glycaemic variability patterns associated with remission status were found to be distinct based on the circadian CGM metrics. Remitters showed improved control of blood glucose levels over 14 days within the range of 3.9-10 mmol/l, and lower GRI compared with non-remitters (p<0.001). Moreover, GRI strongly correlated with IDAA1C (r=0.62; p<0.001) and was sufficient to distinguish remitters from non-remitters. Further, four subgroups demonstrating distinct patterns of glycaemic variability associated with different remission status were identified by clustering on CGM metrics: remitters with low risk of dysglycaemia; non-remitters with high risk of hypoglycaemia; non-remitters with high risk of hyperglycaemia; and non-remitters with moderate risk of dysglycaemia.Conclusions/interpretation: GRI, an integrative index, together with other traditional CGM metrics, helps to identify different glycaemic variability patterns; this might provide specifically tailored monitoring and management strategies for individuals in the various subclusters.

Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy.

Predictors Of Long-Term Glycemic Remission After 2-Week Intensive Insulin Treatment In Newly Diagnosed Type 2 Diabetes

1,5-Anhydroglucitol is Associated with Early-Phase Insulin Secretion in Chinese Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Association between 1,5-Anhydroglucitol and Acute C Peptide Response to Arginine among Patients with Type 2 Diabetes

Saliva 1,5-Anhydroglucitol is Associated with Early-Phase Insulin Secretion in Chinese Patients with Type 2 Diabetes.

1,5-Anhydroglucitol Predicts Mortality in Patients with HBV-Related Acute-on-chronic Liver Failure

Relationship Between 1,5-Anhydroglucitol and Renal Function Assessed by Dynamic Renal Scintigraphy in Type 2 Diabetes.

Prognostic Value of Serum 1,5-anhydroglucitol Levels in Patients with Acute Myocardial Infarction

Remission of Hyperglycemia Following Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetic Patients: a Long-Term Follow-Up Study.

The role of monitoring plasma 1,5-anhydroglucitol in newly diagnosed type 2 diabetic patients

Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients is Associated with Improvement of Beta-Cell Function.

Serum 1,5-Anhydroglucitol to Glycated Albumin Ratio Can Help Early Distinguish Fulminant Type 1 Diabetes Mellitus from Newly Onset Type 1A Diabetes Mellitus

Lower Mean Blood Glucose During Short‐term Intensive Insulin Therapy is Associated with Long‐term Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes: Evidence‐based Recommendations for Standardization

Serum 1,5-anhydroglucitol levels slightly increase rather than decrease after a glucose load in subjects with different glucose tolerance status

Serum 1,5-Anhydroglucitol when Used with Fasting Plasma Glucose Improves the Efficiency of Diabetes Screening in a Chinese Population

Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients

A Study On The Association Of Serum 1,5-Anhydroglucitol Levels And The Hyperglycaemic Excursions As Measured By Continuous Glucose Monitoring System Among People With Type 2 Diabetes In China

Optimal 1,5-anhydroglucitol cut-off points for diagnosing diabetes based on prevalence of retinopathy in Chinese population

Nonlinear Association of 1,5-Anhydroglucitol with the Prevalence and Severity of Coronary Artery Disease in Chinese Patients Undergoing Coronary Angiography

Combining Serum 1,5-Anhydroglucitol with Fasting Plasma Glucose to Detect Diabetes Mellitus in a Community-Based Population with Hypertension

Glycaemia Risk Index Uncovers Distinct Glycaemic Variability Patterns Associated with Remission Status in Type 1 Diabetes.